NCT02303392 2025-06-10
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
Clinical Trials
4 trialsNCT03992339 2025-02-07
SEARCH
Antengene Corporation
Phase 2 Completed
NCT03955783 2024-10-26
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT02471911 2022-04-12
KPT-330+RICE
Weill Medical College of Cornell University
Phase 1 Completed